<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00969046</url>
  </required_header>
  <id_info>
    <org_study_id>CEPO906A2117</org_study_id>
    <nct_id>NCT00969046</nct_id>
  </id_info>
  <brief_title>Dose-Escalation Study in Advanced Colon Cancer Patients</brief_title>
  <official_title>EPO906 Phase I 6-arm Trial to Optimize Administration Exploring Single Dose Bolus and Continuous Infusion Over 1 or 5 Days Every 3 or 4 Weeks in Patients With Pretreated Advanced Colon Cancer With Nutritional Support Treatment and Intensive Management of Diarrhea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is exploring different administration schedules (short versus prolonged infusion)
      to optimize the safety and efficacy profile of EPO906A (patupilone) in patients with
      pretreated advanced colon cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To identifymaximum tolerated dose (MTD)</measure>
    <time_frame>During cycle 1 and 2 (approx 6 to 8 wks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To characterize the safety and tolerability of patupilone by assessing adverse events (AEs) and serious adverse events (SAEs), hematology and biochemistry labs, vital signs, performance status, and by physical/neurological exams</measure>
    <time_frame>at base line, every 3 weeks prior to start of the next dose, at end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate preliminary anti-tumor activity of patupilone using standard imaging technologies (e.g. best overall response rate and time to progression according to Response Evaluation Criteria in Solid Tumors [RECIST])</measure>
    <time_frame>at baseline and every 8 wks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the blood concentrations profile (pharmacokinetics [PK]) of patupilone by multiple blood sampling before, during and after drug administration</measure>
    <time_frame>Cycle 1 and 4</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Colon Cancer</condition>
  <arm_group>
    <arm_group_label>Bolus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 min bolus infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CIV-1d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 day continuous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CIV-5d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 day continuous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPO906 (patupilone)</intervention_name>
    <arm_group_label>Bolus</arm_group_label>
    <arm_group_label>CIV-1d</arm_group_label>
    <arm_group_label>CIV-5d</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed, locally advanced, progressive or metastatic colon cancer, up
             to 4 prior lines of prior chemotherapy, at least one measurable lesion according to
             RECIST

          2. Age ≥ 18 years

          3. Life expectancy ≥ 12 weeks

          4. WHO performance status of 0-1

          5. Negative serum pregnancy test

          6. Adequate hepatic or renal function and hematological parameters

        Exclusion Criteria:

          1. Brain metastases

          2. Ileostomy or colonostomy

          3. History of pelvic radiotherapy

          4. Grade &gt; 1 diarrhea at baseline

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Royal London Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hradec Králové</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint-Herblain Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2009</study_first_submitted>
  <study_first_submitted_qc>August 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2009</study_first_posted>
  <last_update_submitted>April 20, 2016</last_update_submitted>
  <last_update_submitted_qc>April 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colon cancer</keyword>
  <keyword>MTD</keyword>
  <keyword>DLT</keyword>
  <keyword>EPO906</keyword>
  <keyword>patupilone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epothilone B</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

